Environmental Services

Size: px
Start display at page:

Download "Environmental Services"

Transcription

1 INDEPENDENT RESEARCH 19th May 2017 Environmental Services Environmental Services What if we bet on a further macro recovery SUEZ BUY FV EUR17.5 vs Bloomberg SEV FP Reuters SEVI.PA Price EUR High/Low /12.77 Market cap. EUR9,768m Enterprise Val EUR22,977m PE (2017e) 21.1x EV/EBIT (2017e) 16.5x VEOLIA ENVIRONNEMENT NEUTRAL FV EUR19.5 Bloomberg VIE FP Reuters VIE.PA Price EUR High/Low / Market Cap. EUR10,684m Enterprise Val EUR17,582m PE (2017e) 17.8x EV/EBIT (2017e) 12.8x /05/17 Source Thomson Reuters STOXX EUROPE 600 UTILITIES E STOXX EUROPE 600 In this report, we model what would be the impact for both Suez and Veolia of a stronger recovery in European industrial production. Both companies would clearly benefit from such a recovery. If all the planets are aligned across the groups different segments, we computed that our FVs would be positively impacted by up to 11%, according to our estimates. Following the stronger than expected Q1-17 publications of both Suez and Veolia, we decided to model what would be the impact of a further recovery in European industrial production. Clearly, both companies would benefit from such a recovery with Suez likely to benefit the most given 1/ the strong correlation observed between waste s organic growth and industrial output; and 2/ the particular cost structure of the business. Assuming all the planets are aligned across the companies different segments this would be our best case scenario we computed that our FVs, for both Suez and Veolia, could be positively impacted by up to 11% according to our estimates, highlighting therefore that 1/ the regain in investors confidence is not usurped in our view and 2/ there is still potential upside despite the shares recent strong outperformance. Our estimates remain unchanged for Veolia, as do our FV at EUR19.5 and our Neutral rating. For Suez, our EBITDA estimates have been increased by c. 1.0% on average, while our EPS forecasts have been revised upward by c. 6.5% on average on the back of adjustments inherent to the recently unveiled capital increase scheme. Consequently, our FV is increased to EUR17.5 vs. EUR16.5 and our Buy rating confirmed. Veolia s valuation appears attractive at first sight with a still c. 9% discount vs. Suez (P/E ratio level). However, this discount remains justified, in our view, given Suez s higher growth profile (+11.0% EPS growth expected over e vs. +9.0% for Veolia). Looking at PEG ratios, it appears that Suez is actually trading at a c.7.5% discount to Veolia, on average, over the period. Analyst: Pierre-Antoine Chazal 33(0) pachazal@bryangarnier.com r r

2 Table of contents 1. We still prefer Suez to Veolia Macro-indicators appear better oriented for both France and the Eurozone Detailing Suez s and Veolia s respective exposures to the waste segment Sensitivity analysis Recovery in European industrial production could boost Suez s and Veolia s earnings What if all the planets are aligned Estimates change to our Veolia estimates Tweaking our Suez estimates A word on multiples and valuation A quick word on multiples Valuation Price Chart and Rating History Price Chart and Rating History Bryan Garnier stock rating system... 19

3 1. We still prefer Suez to Veolia Since the beginning of Q2-17, the shares of both Suez and Veolia have strongly outperformed the market notably on the back of the enhanced confidence in key Eurozone macro indicators. Both companies Q1-17 results were stronger than expected due to the solid performance in their respective waste businesses activities. Veolia posted 5.6% organic growth in its waste revenues, notably spurred by a 1.2% increase in processed volumes. Suez posted 7.4% organic growth in its recycling & recovery business unit, similarly spurred by a 1.9% increase in processed volumes. Fig. 1: Strong increase in Veolia s and Suez s share prices YTD Dec-16 Jan-17 Jan-17 Jan-17 Jan-17 Feb-17 Feb-17 Feb-17 Feb-17 Mar-17 Mar-17 Mar-17 Mar-17 Mar-17 Apr-17 Apr-17 Apr-17 Apr-17 May-17 May-17 Veolia Suez Source: Thomson Reuters; Bryan, Garnier & Co ests. In this short report, we model what would be the impact of a stronger than expected recovery in European industrial production on Suez s and Veolia s metrics and valuations. According to our estimates, a 1% increase in waste volumes processed would lead to clear earnings growth for both companies with: A c. EUR35m and c. EUR30m positive impact on Suez s and Veolia s respective EBITDA; A c. 5.0% and c. 3.5% positive impact on Suez s and Veolia s respective earnings per share, on average, over 2017e-2019e; A EUR1.0 and a EUR0.9 per share positive impact on our current FV for Suez (c. 5.5% of our current FV) and Veolia (c.4.5% of our current FV), respectively. As a consequence, in our view, we believe Suez would benefit the most from such a recovery as the company has a greater exposure than Veolia to the waste segment and a greater exposure to France within that segment. Assuming all the planets are aligned for both companies (best case scenario) in the waste segment as well as in the water segment, or in their respective ability to integrate new or recently- 3

4 acquired companies we computed that our fair values would be positively impacted by between 8% and 11%, highlighting then that 1/ the regain in investors confidence is not usurped in our view and 2/ there is still upside despite the shares strong outperformance over the past few weeks. In all, our estimates remain unchanged for Veolia following our recent post-q1-17 results update (see our morning mail: Stronger than expected top-line growth drives slightly up our estimates). Our FV at EUR19.5 per share as well as our Neutral recommendation are maintained. We were positively surprised by the higher than expected top-line growth in Q1-17 but we are still struggling to find more upside in our SOTP valuation. Moreover, the operating leverage remains rather weak at this stage, mainly due to increased commercial charges, still strong downsizing of construction activities and the poor EBITDA impact coming from the recovery in recycled prices. As for Suez, our estimates have been slightly revised upward at the EBITDA level (+1.0% on average over 2017e-2020e). Our EPS post-hybrid coupons forecasts have been significantly increased (+6.5% on average over the same period) on the back of the previously mentioned EBITDA increase as well as the adjustments inherent to the recently unveiled capital increase scheme. As a consequence, our FV is revised upward to EUR17.5 per share. Our Buy recommendation is confirmed. Veolia s valuation appears attractive at first sight with, still, a c. 9% discount (P/E ratio level) vs. Suez. However, this discount remains justified, in our view, given Suez s higher growth profile (+11.0% EPS growth expected e vs. +9.0% for Veolia). Looking at PEG ratios, it appears that Suez is actually trading at a 7.5% discount to Veolia, on average, over the period. 4

5 2. Macro-indicators appear better oriented for both France and the Eurozone Eurozone macro indicators appear well oriented since the beginning of the year. In April 2017, the Eurozone manufacturing PMI reached 56.7 up c. 10% yoy a level which had not been reached since mid Similarly, in France, the manufacturing PMI reached 55.1 in April 2017, the highest level since December This partly explains, in our view, why Veolia and Suez have regained investors confidence over the past few months. Fig. 2: Highest PMI levels in France and the Eurozone since 2010/2011 Eurozone PMI ( ) France PMI ( ) Feb-08 Jun-08 Oct-08 Feb-09 Jun-09 Oct-09 Feb-10 Jun-10 Oct-10 Feb-11 Jun-11 Oct-11 Feb-12 Jun-12 Oct-12 Feb-13 Jun-13 Oct-13 Feb-14 Jun-14 Oct-14 Feb-15 Jun-15 Oct-15 Feb-16 Jun-16 Oct-16 Feb Aug-08 Dec-08 Apr-09 Aug-09 Dec-09 Apr-10 Aug-10 Dec-10 Apr-11 Aug-11 Dec-11 Apr-12 Aug-12 Dec-12 Apr-13 Aug-13 Dec-13 Apr-14 Aug-14 Dec-14 Apr-15 Aug-15 Dec-15 Apr-16 Aug-16 Dec-16 Apr-17 Source: Markit, Bloomberg, Bryan, Garnier & Co ests. As a reminder, we already highlighted in the past that both GDP and industrial production can be perceived as good proxies to the waste segment. Historically, we observed a strong correlation between the evolution of industrial production and the organic growth of Veolia s and Suez s respective waste segments (correlation estimated at between 0.7 and 0.8). Fig. 3: Strong correlation observed between waste organic growth and industrial production indices 5

6 Source: Veolia (Q1-17 presentation). Weighted average industrial production indices for 4 key countries (France, UK, Germany and rth America) with January and February 2017 figures being OECD figures for all countries The latest consensus forecasts for both Eurozone GDP and industrial production currently stand at +1.7% and +1.85%, respectively, for Forecasts have been consistently revised upward over the past few months (+1.4% in December 2016 to 1.7% today for 2017 GDP and +1.3% in December 2016 to +1.85% today for 2017 industrial production). Fig. 4: Evolution of GDP and industrial production consensus forecasts for the Eurozone GDP (%) Industrial production (%) Eurozone 2017e 2018e 2017e 2018e Current 1.7% 1.6% 1.85% 1.8% April % 1.5% 1.8% 1.7% March % 1.5% 1.6% 1.6% February % 1.5% 1.5% 1.6% December % - 1.3% - Source: Bloomberg; Bryan, Garnier & Co ests. 6

7 3. Detailing Suez s and Veolia s respective exposures to the waste segment We believe that both Suez and Veolia would benefit from a clear recovery in European industrial production on the back of their respective strong exposures to the previously mentioned waste segment. But, in all, we consider that Suez will benefit the most from such a recovery as: Suez has a stronger exposure than Veolia in the waste segment; Suez has a stronger exposure than Veolia in the French waste sub-segment. We indeed estimated that Suez generates around EUR7.5bn of revenues in the waste segment, i.e. around 43% of the group s revenues, following the recent acquisition of GE Water. This appears to be higher than Veolia (34% of FY-16 revenues) with this latter also being exposed to the energy segment (20% of Veolia s FY-16 revenues) following the Dalkia operation back in We estimated that Veolia generates around EUR8.5bn of revenues in the waste segment. The EBITDA margins of these waste segments are not fully disclosed by the companies as Suez only unveiled EBITDA for its Recycling & Recovery (R&R) segment (c. 16% of the group s waste revenues are reported in the company s International division) and Veolia now reports by geography. R&R EBITDA margins are usually to the tune of 12%, which is close to what Veolia used to report in its waste segment before the changes in reporting. This 12.0% EBITDA margin could then appear as a good proxy in order to assess respective EBITDA exposures to the waste segment. This would imply that Suez and Veolia have a respective c. EUR900m and c. EUR1bn EBITDA in the waste segment, i.e. c 35% and 33% of the overall groups EBITDA. The strong discrepancy observed for Suez (43% exposure at the top-line level vs. a 35% exposure at the EBITDA level) actually highlights that waste margins are lower than the group s ones with, as a reminder, Suez being notably exposed to regulated activities (46% EBITDA margin for US regulated water activities and c. 58% EBITDA margin for Chilean regulated water activities). Fig. 5: Suez s and Veolia s respective revenue exposure to the waste segment Suez s revenue breakdown inc. GE Water (2016 data) Veolia s revenue breakdown (2016 data) Energy 20% Waste 43% Water 46% Water 57% Waste 34% Source: Suez, Veolia, Bryan, Garnier & Co ests. 7

8 On the basis of the different figures unveiled by both companies, we tried to reconstitute in detail Suez and Veolia s respective geographical breakdown of their waste businesses. We estimated that around 30% of Veolia s waste revenues is generated in France, 21% in the UK, 11% and Germany, 8% in the USA and 9% in Australia. In the end, we estimated that around 65% of Veolia s waste revenues is generated in Europe. Fig. 6: Geographical breakdown of Veolia s estimated waste revenues Others Asia 2% Others 13% Latam 5% China 1% France 30% Australia 9% USA 8% Germany 11% UK 21% As for Suez, we estimated that around 44% of the company s waste revenues is generated in France, 20% in Benelux and in Germany, 17% in the UK and in Scandinavia and around 10% in Australia. In the end, we estimated that around 85% of Veolia s waste revenues is generated in Europe. Fig. 7: Geographical breakdown of Suez s estimated waste revenues Australia 10% Others 6% Central Europe 3% France 44% Benelux/Germany 20% UK/Scandinavia 17% 8

9 4. Sensitivity analysis 4.1. Recovery in European industrial production could boost Suez s and Veolia s earnings We estimated that a +/- 1% change in European waste volumes has a c. EUR30-35m impact on Suez s and Veolia s EBITDA, on an annual basis. This is mainly due to the particular cost structure of the waste business with fixed costs usually representing between 50% and 60% of overall costs. We estimated the impact should be slightly higher for Suez (c. EUR35m) than for Veolia (c. EUR30m). This is based on the following assumptions: 1/ the EBITDA margin of waste businesses at 12.0%; 2/ fixed costs representing 50% of the overall business costs; 3/ we estimated that about 65% and 85% of Veolia s and Suez s respective waste revenues are generated in Europe (cf. pie chart above). Fig. 8: +1% change in European waste volumes estimated EBITDA impact for Suez Estimated current +1% in European Waste metrics waste volumes Estimated waste revenues (EURm) P&L impact % generated in Europe (%) 85.0% - European waste revenues (EURm) 6,382 6, Fixed costs (EURm) (2,808) (2,808) 0 Variable costs (EURm) (2,808) (2,836) (28) EBITDA (EURm) EBITDA margin (%) 12.0% 12.4% - Fig. 9: +1% change in European waste volumes estimated EBITDA impact for Veolia Estimated current +1% in European Waste metrics waste volumes Estimated waste revenues (EURm) P&L impact % generated in Europe (%) 65% - European waste revenues (EURm) 5,461 5, Fixed costs (EURm) (2,403) (2,403) 0 Variable costs (EURm) (2,403) (2,427) (24) EBITDA (EURm) EBITDA margin (%) 12.0% 12.4% - As a consequence, we estimated this tailwind coming from a 1.0% increase in European processed volumes would have a c. 5.0% positive impact on Suez s EPS (post-hybrid coupons, on average over our 2017e-2019e estimates, based on a 30% normative tax rate) and a c. 3.5% 9

10 positive impact on Veolia s EPS (post-hybrid coupons, on average over our 2017e-2019e estimates, based on a 30% normative tax rate). Fig. 10: +1% change in European waste volumes estimated EPS impact for Suez Suez 2017e 2018e 2019e Average Additional Profit Before Taxes Taxes (based on a 30% normative tax rate) (10.8) (10.8) (10.8) - Additional Net Income Current Net Income (BG estimates) # shares Current EPS (BG estimates, post hybrid coupon) New EPS (inc. additional NI contribution) Estimated impact on EPS (%) 5.7% 4.6% 4.2% 4.9% Fig. 11: +1% change in European waste volumes estimated EPS impact for Veolia Veolia 2017e 2018e 2019e Average Additional Profit Before Taxes Taxes (based on a 30% normative tax rate) (9.3) (9.3) (9,3) - Additional Net Income Current Net Income (BG estimates) # shares Current EPS (BG estimates, post-hybrid coupon) New EPS (inc. additional NI contribution) Estimated impact on EPS (%) 4.1% 3.3% 3.0% 3.5% As our assumptions for waste volumes processed are built on a mark-to-market basis, we estimated that a similar + 1.0% increase in volumes would have an EUR1.0 per share positive impact on our FV for Suez (c. 5.5% of our current FV) and an EUR0.9 per share positive impact on our FV for Veolia (4.6% of our current FV). This is based on a DCF-proxy basis with a 5.9% WACC (notably based on a 1.6% risk-free rate, on a 7.0% market premium and a 1.0 beta). Fig. 12: Suez Impact on our FV coming from a +1% increase in waste volumes Year TV Additional EBITDA % WACC Present Value 267 Terminal Value 327 Enterprise Value 594 # shares 611 Impact Equity Value/sh

11 Fig. 13: Veolia Impact on our FV coming from a +1% increase in waste volumes Year TV Additional EBITDA % WACC Present Value 230 Terminal Value 280 Enterprise Value 510 # shares 569 Impact Equity Value/sh What if all the planets are aligned We tried to assess what would be the impact on our current FV (for both Veolia and Suez) of various particular items across Veolia s and Suez s different business divisions. These include the following assumptions: For Veolia: Increase in processed waste volumes of +2.0% and +2.5% on the back of a stronger recovery in European industrial production vs. +1.2% currently in our model (mark-to-market); Stronger than expected tariff increases in the French water segment (+1.5% vs. +1.0% in our model) as from 2018 on the back of higher inflation and a stronger increase in energy prices; Faster than expected recovery of the company s construction and engineering activities (VWT and SADE subsidiaries) with BG targeted EBITDA margins being reached one year ahead of schedule; More bolt-on acquisitions than in our current expectations (we currently expect Veolia to acquire new assets for c. EUR500m at an 9.0x EV/EBITDA multiple). According to our computations, these new assumptions could raise our FV by between EUR1.55 and EUR2.0 per share which would lead to a FV between EUR21 and EUR21.5. Fig. 14: Veolia Base case vs. best case scenario Base case Best case Impact FV +1.2% mark-to-market volumes' increase in line with Q1-17 figures French water: +1.0% average tariff increase in 2018 & beyond Bolt-on acquisitions: 500m over 9.0x EV/EBITDA VWT: 5.3% EBITDA margin in 2019 & SADE: 4.0% in %-+2.5% increase in processed volumes +0.70/ % average tariff increase Acquisitions x2: EUR1bn, 9.0x EV/EBITDA multiple Target margins reached one year ahead of BG schedule Potential impact on our FV /+2.00 Current FV vs. potential new FV

12 For Suez: Increase in processed waste volumes of +2.0% and +2.5% on the back of a stronger recovery in European industrial production vs. +1.2% currently in our model (mark-to-market); Stronger than expected tariff increases in the French water segment (+1.5% vs. +1.0% in our model) as from 2018 on the back of higher inflation and a stronger increase in energy prices; EBITDA s organic growth of GE Water at 5.0% over 2018e-2021e, in line with Suez s initial expectations (vs. +3.5% currently in our model) According to our computations, these new assumptions could raise our FV by between EUR1.45 and EUR1.9 per share which would lead to a FV between EUR19.0 and EUR19.5. Fig. 15: Suez Base case vs. best case scenario Base case Best case Impact FV +1.2% mark-to-market volumes' increase +2.0%-+2.5% increase in processed volumes +0.80/+1.25 French water: +1.0% average tariff increase in 2018 & beyond +1.5% average tariff increase GE Water: 3.5% EBITDA organic growth over 2018e-2021e 5.0% EBITDA organic growth over 2018e-2021e in line with Suez s initial expectations Potential impact on our FV /+1.90 Current FV vs. potential new FV

13 5. Estimates 5.1. change to our Veolia estimates On Veolia, our estimates as well as our valuation remain unchanged at this stage. As a reminder, we recently revised upward both our forecasts and our FV (from EUR18.5 to EUR19.5 per share) following, notably, stronger than expected top-line growth observed in Q1-17 (see our morning mail: Stronger than expected top-line growth drives slightly up our estimates). For 2017e, we still expect FY 2017 EBITDA to grow c. 1.3% organically (excluding the impact of Vilnius, flat including Vilnius) and at c. 2.7% at constant FX (excluding Vilnius, +1.6% including Vilnius). EBITDA should still be negatively impacted by negative tariff indexations in the French water business and increased commercial charges, while the recovery in recycled prices is likely to have a fairly marginal impact on the group s EBITDA. We, however, expect EBITDA growth to speed up in both FY 2018e and FY 2019e with our FY 2019e EBITDA estimate standing at EUR3,441m (excluding IFRIC 12 adjustment), at the high-end of the company s guidance of EUR bn (excluding IFRIC 12 adjustment). Fig. 16: BG s current estimates for Veolia (2017e-2019e) Key BG estimates 2017e 2018e 2019e Revenues 24,916 25,483 26,152 EBITDA (exc. IFRIC 12) 3,106 3,301 3,441 EBITDA margin % 12.5% 13.0% 13.2% EBITDA (inc. IFRIC 12) 3,306 3,501 3,641 EBITDA margin % 13.3% 13.7% 13.9% Current EBIT (exc. IFRIC 12) 1,373 1,537 1,639 Current Net Income Current EPS DPS Tweaking our Suez estimates Just like Veolia at the beginning of the month, Suez reported strong growth in revenues in its waste business division in Q1-17 (+7.4% on an organic basis). This was the consequence of the substantial rebound in recycled prices yoy but principally of the stronger than expected increase in processed volumes (+1.9% yoy vs. +1.2% for Veolia). As a consequence, our assumptions for volume growth are raised by c. 50bps on average over the period. As a reminder, in order to be conservative, we initially modelled the EUR750m capital increase needed to partly fund the acquisition of GE Water via a rights issue with a c. 20% discount TERP (based on Suez s closing price as of 03/28/2017). Few days ago, Suez finally announced the launch of its capital increase with the operation being carried in two stages: 1/the company s existing shareholders will be granted a three-day priority subscription period on an irreducible basis which will run from 17 th -19 th May, and 2/the new shares not subscribed for during the subscription period are to be offered in a global offering (private placement executed through ABB on 16 th May). The subscription price has been set at EUR15.8 per share in the low-end of the initial guidance of EUR per share which implies a 2.8% discount vs. Suez s last closing price before the operation. Such an operation implies the creation of about 47m new shares, well below our initial 13

14 conservative assumptions (c. 69m new shares). As a consequence, this operation has a c. 3.0% positive impact, on average, on our initial 2017e-2020e EPS estimates as well as a EUR0.6 per share positive impact on our FV, all being equal. In all, the adjustments we made in the waste business division as well as the integration of the previously mentioned capital increase scheme led us to revised upward our EBITDA estimates by 1.0% on average over 2017e-2020e and our EPS post-hybrid coupons forecasts by 6.5% on average over the same period. te that our EPS estimates are also positively impacted by the lower than expected coupons related to both hybrid (EUR600m at 2.875% vs. 4% initially in our model) and LT senior (EUR500m at 1.0% and EUR700m at 1.5% vs. EUR1.1bn at 1.5% initially in our model) debts Suez issued a few weeks ago. Fig. 17: Key changes in our Suez estimates (2017e-2020e) New BG estimates (2017e-2020e) 2017e 2018e 2019e 2020e Average change in our estimates (2017e- Revenues 16,743 18,357 18,864 19, % EBITDA 2,863 3,158 3,287 3, % EBIT 1,395 1,621 1,720 1, % EPS pre hybrid % EPS post hybrid % 2020e) 14

15 6. A word on multiples and valuation 6.1. A quick word on multiples Suez currently trades at 19.9x and at 17.3x its 2017e and 2018e P/E ratios, respectively. This appears to be bang in line vs. its 3-year historical average for both FY+1 and FY+2 P/E ratios. This also implies a c. 9% premium, on average, vs. Veolia. At first sight, Veolia is therefore trading at a high-single digit discount vs. Suez. Fig. 18: At first sight, Veolia is trading at a strong discount vs. Suez Company 2017 P/E 2018 P/E Premium/Discount vs. Suez/Veolia 2017e Premium/Discount vs. Suez/Veolia 2018e Premium/Discount vs. 3-year P/E Y1 average Premium/Discount vs. 3-year P/E Y2 average Suez 19.9x 17.3x 9.3% 11.6% (1.0%) (0.6%) Veolia 18.2x 15.5x (8.5%) (10.4%) (24.8%) (13.9%) In our view, this premium is, however, justified as Suez is likely to benefit from higher EPS growth, compared to Veolia, over e (+11.0% EPS growth over the period vs. +9.0% for Veolia), notably on the back of the expected accretion inherent to the GE Water acquisition. Looking at PEG ratios (PE/earnings growth) over e, Suez is actually trading at a c. 7.5% discount to Veolia, on average, over the period. Fig. 19: PEG ratio 2017e-2019e for Suez & Veolia EPS CAGR PE ratio PE ratio PE ratio PEG ratio PEG ratio PEG ratio 2019e FY-17e FY-18e FY-19e FY-17e FY-18e FY-19e Suez 11.0% 19.9x 17.3x 16.1x 1.81x 1.57x 1.46x Veolia 9.0% 18.2x 15.5x 13.7x 2.02x 1.72x 1.52x Source : Bryan Garnier & Co. ests Valuation Just like our estimates, our valuation remains unchanged for Veolia. As a consequence, our EUR19.5 per share FV is maintained and still implies a very limited upside to the tune of 3.0%. As for Suez, we revised upward our FV from EUR16.5 to EUR17.5 per share on the back of the increase in our estimates and the adjustments linked to a different capital increase scheme. As a reminder, we used a 9.5x EV/EBITDA multiple to value the company s regulated water assets in the US and a 9.0x EV/EBITDA multiple for the company s regulated water assets in Chile. This 5% discount (9.0x for Chile vs. 9.5x for the US activities) is still due to ongoing regulatory uncertainties in the country (potential downward revision of the assets remuneration). 15

16 Fig. 20: Suez Sum-of-the-parts (SOTP) Suez SOTP valuation Value (EURm) Method Value per share Water Europe - n regulated 5,743 Discounted CF 9.4 Aguas Andinas Regulated water Chile 3, x FY-17e EV/EBITDA multiple 6.1 Recycling & Recovery Europe 6,754 Discounted CF 11.1 International - Excluding United Water Regulated 4,594 Discounted CF 7.5 United Water Regulated Water US 2,316 Others (816) 9.5x FY-17e EV/EBITDA multiple 6.0x FY-17e EV/EBITDA multiple 3.8 (1.3) GE Water 3,607 Discounted CF 5.9 Implied Enterprise Value (EV) 25, Net debt at end 2017e 9,213 - (15.1) Integration of hybrid 100% (1,600) - (2.6) Provisions (2,062) Book Value (3.4) Minority interest (3,147) 14x P/E for non-regulated assets 17x P/E for regulated assets (5.1) New minorities inherent to GE Water s transaction (1,082) 30% of GEW EV (1.8) Financial assets 1,900 Book Value 3.1 o/w Associates (exc. ACEA, already integrated in our EV) 785 Book Value 1.3 o/w other financial assets 1,115 Book Value 1.8 Total implied Equity value 10, Number of shares (m) Equity value per share (rounded)

17 Price Chart and Rating History Veolia Environnement /11/15 18/02/16 18/05/16 18/08/16 18/11/16 18/02/17 18/05/17 VEOLIA ENVIRONNEMENT Fair Value Achat Neutre Vente Ratings Date Ratings Price 06/01/17 NEUTRAL EUR /06/16 BUY EUR /11/15 NEUTRAL EUR /09/14 BUY EUR Target Price Date Target price 09/05/17 EUR /03/17 EUR /01/17 EUR /11/16 EUR22 02/08/16 EUR /06/16 EUR23 20/04/16 EUR22 15/12/15 EUR /07/15 EUR22 02/04/15 EUR20 13/03/15 EUR19 11/02/15 EUR18 30/09/14 EUR17 17

18 Price Chart and Rating History Suez /11/15 18/02/16 18/05/16 18/08/16 18/11/16 18/02/17 18/05/17 SUEZ Fair Value Achat Neutre Vente Ratings Date Ratings Price 08/09/15 BUY EUR /09/14 NEUTRAL EUR Target Price Date Target price 28/03/17 EUR /03/17 Under review 06/01/17 EUR /06/16 EUR /04/16 EUR /04/16 EUR /07/15 EUR19 02/04/15 EUR18 13/03/15 EUR17 09/12/14 EUR16 30/09/14 EUR14 18

19 BUY NEUTRAL SELL Bryan Garnier stock rating system For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows: Stock rating Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion. Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion. Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion. Distribution of stock ratings BUY ratings 47.9% NEUTRAL ratings 36.2% SELL ratings 16% 1 Bryan Garnier shareholding in Issuer 2 Issuer shareholding in Bryan Garnier Research Disclosure Legend Bryan Garnier & Co Limited or another company in its group (together, the Bryan Garnier Group ) has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the Issuer ). The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group. 3 Financial interest A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report 4 Market maker or liquidity provider A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives. 5 Lead/co-lead manager In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives. 6 Investment banking agreement A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services. 7 Research agreement A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report. 8 Analyst receipt or purchase of shares in Issuer The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares. 9 Remuneration of analyst The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group. 10 Corporate finance client In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months. 11 Analyst has short position The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer. 12 Analyst has long position The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer. 13 Bryan Garnier executive is an officer A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person s household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above. 14 Analyst disclosure The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report. 15 Other disclosures Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed). Yes A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at 19

20 London Paris Beaufort House 26 Avenue des Champs Elysées 15 St. Botolph Street Paris London EC3A 7BB Tel: +33 (0) Tel: +44 (0) Fax: +33 (0) Fax: +44 (0) Regulated by the Authorised and regulated by the Financial Financial Conduct Authority (FCA) and Conduct Authority (FCA) the Autorité de Contrôle prudential et de resolution (ACPR) New York 750 Lexington Avenue New York, NY Tel: +1 (0) Fax: +1 (0) FINRA and SIPC member Munich Widenmayerstrasse Munich Germany Important information This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA s Conduct of Business Sourcebook. This report is prepared by Bryan Garnier & Co Limited, registered in England Number and its MIFID branch registered in France Number Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number ) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company s, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report. This Report may not be reproduced, distributed or published by you for any purpose except with the Firm s prior written permission. The Firm reserves all rights in relation to this Report. Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ( Forward Looking Information ) they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information. Disclosures specific to clients in the United Kingdom This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever. tice to US investors This research report (the Report ) was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to Major US Institutional Investors as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY Telephone: This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security. Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies). Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..

Utilities. Looking for the Grail INDEPENDENT RESEARCH. Utilities

Utilities. Looking for the Grail INDEPENDENT RESEARCH. Utilities INDEPENDENT RESEARCH 2nd April 2015 Utilities Utilities Looking for the Grail ALBIOMA BUY FV EUR22 Bloomberg ABIO FP Reuters ABIO.PA Price EUR17.79 High/Low EUR20.96/15.74 Market cap. EUR529m Enterprise

More information

Faurecia. Fair Value EUR62 vs. EUR57 (price EUR60.51) NEUTRAL vs. BUY. An impressive year so far: To date, the new management team has delivered

Faurecia. Fair Value EUR62 vs. EUR57 (price EUR60.51) NEUTRAL vs. BUY. An impressive year so far: To date, the new management team has delivered INDEPENDENT RESEARCH 27th October 2017 Automotive Faurecia The rerating effect is not enough anymore! Fair Value EUR62 vs. EUR57 (price EUR60.51) NEUTRAL vs. BUY Bloomberg Reuters EO FP EPED.PA 12-month

More information

Pennon Group. The benefits of inflation! INDEPENDENT RESEARCH UPDATE. Utilities Fair Value 800p (price p) BUY

Pennon Group. The benefits of inflation! INDEPENDENT RESEARCH UPDATE. Utilities Fair Value 800p (price p) BUY INDEPENDENT RESEARCH UPDATE 21st March 2013 Pennon Group The benefits of inflation! Utilities Fair Value 800p (price 640.00p) BUY Bloomberg Reuters PNN LN PNN.L 12-month High / Low (p) 796.0 / 598.0 Market

More information

LDR Holding. Long-term vision and ambition brings confidence Price USD20.71 Fair Value USD41 (+98%) BUY

LDR Holding. Long-term vision and ambition brings confidence Price USD20.71 Fair Value USD41 (+98%) BUY 25th February 2016 Healthcare LDR Holding Long-term vision and ambition brings confidence Price USD20.71 Fair Value USD41 (+98%) BUY Bloomberg LDRH US Reuters LDRH.OQ 12-month High / Low (USD) 45.7 / 16.8

More information

Environmental Services

Environmental Services INDEPENDENT RESEARCH 30th November 2015 It is time to take a rest on Veolia! PENNON GROUP NEUTRAL FV 800p Bloomberg PNN LN Reuters PNN.L Price 837p High/Low 919.5/713p Market cap. GBP3,451m Enterprise

More information

Utilities. Fighting for growth INDEPENDENT RESEARCH. Utilities

Utilities. Fighting for growth INDEPENDENT RESEARCH. Utilities INDEPENDENT RESEARCH 30th September 2014 Utilities Utilities Fighting for growth VEOLIA ENVIRONNEMENT BUY FV EUR17 Bloomberg VIE FP Reuters VIE.PA Price EUR13.585 High/Low 14.695/11.2155 Market Cap. EUR7,639m

More information

Healthcare. CAR-T: no longer Science Fiction INDEPENDENT RESEARCH. Healthcare. 8th November 2017

Healthcare. CAR-T: no longer Science Fiction INDEPENDENT RESEARCH. Healthcare. 8th November 2017 INDEPENDENT RESEARCH 8th vember 2017 Healthcare Healthcare CAR-T: no longer Science Fiction CELLECTIS NEUTRAL FV EUR23 Resuming coverage BUY FV EUR9999 Reuters ALCLS.PA Price EUR24.41 High/Low EUR23.6

More information

Zurich Insurance Group

Zurich Insurance Group INDEPENDENT RESEARCH 3 rd February 2014 A new hope for 2014 Insurance Fair Value CHF311 vs. CHF300 (price CHF264.00) BUY Bloomberg Reuters ZURN VX ZURN.VX 12-month High / Low (CHF) 273.3 / 228.8 Market

More information

biomérieux Short-term pain, long-term gain INDEPENDENT RESEARCH UPDATE Fair Value EUR69 vs. EUR66 (price EUR71.28) NEUTRAL Healthcare

biomérieux Short-term pain, long-term gain INDEPENDENT RESEARCH UPDATE Fair Value EUR69 vs. EUR66 (price EUR71.28) NEUTRAL Healthcare INDEPENDENT RESEARCH UPDATE 9th October 2013 Healthcare biomérieux Short-term pain, long-term gain Fair Value EUR69 vs. EUR66 (price EUR71.28) NEUTRAL Bloomberg BIM FP Reuters BIOX.PA 12-month High / Low

More information

Dollarama Inc. Q4 F2017 Results. A straight-forward beat and other notable business updates HIGHLIGHTS. The NBF Daily Bulletin.

Dollarama Inc. Q4 F2017 Results. A straight-forward beat and other notable business updates HIGHLIGHTS. The NBF Daily Bulletin. DOL (T) $110.88 Stock Rating: Outperform (Unchanged) Target: $122.00 (Was $113.00) Risk Rating: Below Average (Unchanged) Est. Total Return: 10.4% Stock Data: 52-week High-Low (Canada) Bloomberg $104.94

More information

Dollarama Inc. Q2 F2017 Preview. (1) Growth expected to continue (2) A deeper look at valuation HIGHLIGHTS. The NBF Daily Bulletin.

Dollarama Inc. Q2 F2017 Preview. (1) Growth expected to continue (2) A deeper look at valuation HIGHLIGHTS. The NBF Daily Bulletin. DOL (T) $97.04 Stock Rating: Outperform (Unchanged) Target: $105.00 (Was $104.00) Risk Rating: Average (Unchanged) Est. Total Return: 8.6% Stock Data: 52-week High-Low (Canada) Bloomberg $98.94 - $66.32

More information

Norges Bank Review 24 September 2015

Norges Bank Review 24 September 2015 Norges Bank Review 24 September 2015 A 25bp rate cut and an easing bias Frank Jullum Chief Analyst fju@danskebank.dk www.danskebank.com/research Arne Lohmann Rasmussen Chief Analyst klom@danskebank.dk

More information

Very solid Q3; excellent story, but priced in; TP upped to 60.00; downgrade to neutral. Q3 2016: Very solid quarter, better than expected

Very solid Q3; excellent story, but priced in; TP upped to 60.00; downgrade to neutral. Q3 2016: Very solid quarter, better than expected B a sl er A G # $T ypcap$ 1576 14 1 1 x 6495 2 Page 1/6 First Take Reco. lowered Neutral vs Buy Electronics Germany Neutral Target price : 60.00 EUR vs 52.00 EUR Price (11/01/2016) : 58.04 EUR Upside :

More information

CEMEX Cement. Quarterly Report February 9, CEMEX remains on track to regain its investment grade.

CEMEX Cement. Quarterly Report February 9, CEMEX remains on track to regain its investment grade. Quarterly Report CEMEX Market Outperformer 2017 Price Target US$11.0 Price 8.9 12M Price Range 4.1/9.5 Shares Outstanding (Mill)* 1,545 Market Cap USD (Mill) 13,797 Float 78.6% Net Debt USD (Mill)** 12,516

More information

CEMEX Cement. Quarterly Report July 27, CX: Proving the success of its Value-before-Volume strategy.

CEMEX Cement. Quarterly Report July 27, CX: Proving the success of its Value-before-Volume strategy. Quarterly Report CEMEX Market Outperformer 12M FWD Price Target US$10.8 Price 7.1 12M Price Range 3.8/8.6 Shares Outstanding (Mill)* 1,542 Market Cap USD (Mill) 10,976 Float 78.6% Net Debt USD (Mill)**

More information

Maruti Suzuki. Source: Company Data; PL Research

Maruti Suzuki. Source: Company Data; PL Research Healthy operating performance; Accumulate October 28, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating Accumulate Price Rs5,860 Target Price Rs6,356 Implied Upside 8.5% Sensex 27,916 Nifty

More information

ContextVision. Expecting solid results and awaiting progress update on research program

ContextVision. Expecting solid results and awaiting progress update on research program 1Q17 Preview (report due April 27 th ) April 24 th 2017 Share price: NOK 61.75 Target: NOK 100.00 (unchanged) Risk: Medium ContextVision Key share data Sector Reuters Bloomberg Health Care COVI.OL COV

More information

Qatar National Bank (QNB)

Qatar National Bank (QNB) Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Global Research Investment Update Equity Qatar Banking Sector 15 February, 2016 (QNB) Market Data Bloomberg Code:

More information

TMT. Sector View. Q review and our TMT Top Picks for Q2: we keep Capgemini, add Dialog and remove Infineon and Wirecard.

TMT. Sector View. Q review and our TMT Top Picks for Q2: we keep Capgemini, add Dialog and remove Infineon and Wirecard. Sector View TMT 4th April 2017 Q1 2017 review and our TMT Top Picks for Q2: we keep Capgemini, add Dialog and remove Infineon and Wirecard 1 M 3 M 6 M 31/12/16 Softw.& Comp. 2.5% 8.8% 7.4% 9.4% DJ Stoxx

More information

DKK: foreign investors bought government bonds and treasury bills in August

DKK: foreign investors bought government bonds and treasury bills in August DKK: foreign investors bought government bonds and treasury bills in August Jens Nærvig Pedersen Analyst Danske Bank Markets jenpe@danskebank.dk +45 45 12 8 61 27 September 213 Important disclosures and

More information

Maruti Suzuki. In a league of its own ; Buy. Source: Company Data; PL Research

Maruti Suzuki. In a league of its own ; Buy. Source: Company Data; PL Research In a league of its own ; Buy October 28, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating BUY Price Rs8,115 Target Price Rs9,250

More information

ISRA VISION Neutral

ISRA VISION Neutral Update Note Closing price as of 1/8/17: 142.8 4 September 217 Company / Sector Fair Value Recommendation ISRA VISION 128. Neutral Technology: Machine Vision ( 128.) (unchanged) Solid Q3 leaves company

More information

Coal India. Source: Company Data; PL Research

Coal India. Source: Company Data; PL Research Misses estimates; Higher costs dims hope for earnings recovery February 13, 2017 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Rating Reduce Price Rs325 Target Price Rs320 Implied Upside 1.5%

More information

ContextVision. Solid 2Q and more details on the contract awaited. August 18 th 2014 Share price: NOK Target: NOK Risk: Medium.

ContextVision. Solid 2Q and more details on the contract awaited. August 18 th 2014 Share price: NOK Target: NOK Risk: Medium. August 18 th 2014 Share price: NOK 21.70 Target: NOK 24.00 Risk: Medium ContextVision Key share data Sector Reuters Bloomberg Health Care COVI.OL COV:NO Market Cap (NOKm) 167.9 Net debt (NOKm) -28.6 EV

More information

Advanced Vision Techn Buy

Advanced Vision Techn Buy 16/9/13 16/11/13 16/1/14 16/3/14 16/5/14 16/7/14 16/9/14 16/11/14 16/1/15 16/3/15 16/5/15 16/7/15 MATELAN Research Update Note Closing price as of 13/8/15: 9.16 14 August 215 Company / Sector Fair Value

More information

Pharmaceuticals INDEPENDENT RESEARCH. Pharmaceuticals. Our valuation methodology for big pharmas deserves new adjustments

Pharmaceuticals INDEPENDENT RESEARCH. Pharmaceuticals. Our valuation methodology for big pharmas deserves new adjustments INDEPENDENT RESEARCH 8th April 2013 Pharmaceuticals Our valuation methodology for big pharmas deserves new adjustments Pharmaceuticals ASTRAZENECA BUY 3600p vs. 3520 Last Price 3282.5p Market Cap. GBP41,021m

More information

TVS Motors. Source: Company Data; PL Research

TVS Motors. Source: Company Data; PL Research Margins trajectory looking up ; Accumulate November 01, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs709

More information

Monitor Euro area deflation

Monitor Euro area deflation Investment Research General Market Conditions 17 July 2014 Euro area deflation Inflation outlook Euro inflation remained very low at 0.5% in June and is still far below the ECB s target. In response, the

More information

Turkcell EARNINGS REVIEW 4Q17. Digital transformation on track BUY

Turkcell EARNINGS REVIEW 4Q17. Digital transformation on track BUY EARNINGS REVIEW 4Q17 Turkey Telecom Services 16 February 2018 Turkcell Digital transformation on track We maintain our BUY recommendation for Turkcell with a 12M target price of TRY17.54, which offers

More information

Key estimate revision. Financial summary. Year

Key estimate revision. Financial summary. Year : price: EPS: How does our one year outlook change? We retain our positive outlook on WIL and believe that revival in MHCV industry, increasing content per vehicle and opportunity in exports would drive

More information

MATELAN Research. InVision 49.0 Buy. Excellent margin trend in Prelims. Update Note. 24 February Company / Sector Fair Value Recommendation

MATELAN Research. InVision 49.0 Buy. Excellent margin trend in Prelims. Update Note. 24 February Company / Sector Fair Value Recommendation Update Note Price as of 21/02/13: 4 24 February 2014 Company / Sector Fair Value Recommendation InVision 49.0 Buy Technology: Cloud Computing ( 34) (Buy) Excellent margin trend in Prelims Share price performance

More information

Monitor Euro area credit monitor

Monitor Euro area credit monitor Investment Research General Market Conditions 26 November 2014 Monitor Euro area credit monitor Credit growth outlook The latest improvements in euro-area bank lending are expected to continue. The progress

More information

BUY Target Price, Rp 4,350 Upside 11,9%

BUY Target Price, Rp 4,350 Upside 11,9% Friday, 9 May 214 BUY Target Price, Rp 4,350 Upside 11,9% SMSM IJ/SMSM.JK Last Price, Rp 3,885 No. of shares (bn) 1,439 Market Cap, Rp bn 5,591 (US$ mn) 484 3M T/O, US$mn 0.2 Last Recommendation 09Jan14

More information

Norges Bank Review. Unchanged but September cut still in store. 23 June Follow us on

Norges Bank Review. Unchanged but September cut still in store. 23 June Follow us on Norges Bank Review Unchanged but September cut still in store Frank Jullum Chief Economist +47 85 40 65 40 fju@danskebank.dk Kristoffer Kjær Lomholt Analyst +45 45 12 85 29 klom@danskebank.dk 23 June 2016

More information

Schoeller Bleckmann. Oilfield Services 9 March 2012 BUY BUY. Recent weakness presents good opportunity. Flash Note (SBO AV)

Schoeller Bleckmann. Oilfield Services 9 March 2012 BUY BUY. Recent weakness presents good opportunity. Flash Note (SBO AV) Schoeller Bleckmann Flash Note (SBO AV) BUY BUY Oilfield Services 9 March 2012 Recent weakness presents good opportunity Schoeller Bleckmann s valuation currently stands at a premium compared with its

More information

Dynamics change but net debt continues to rise

Dynamics change but net debt continues to rise EQUITIES IT SERVICES INDRA UNDERPERFORM EUR12.2 TARGET PRICE EUR9 (DOWNSIDE 26%) TARGET PRICE EPS 13e EPS 14e unchanged -16% -14% Dynamics change but net debt continues to rise 1 NOVEMBER 2013 Brice Prunas

More information

BIMBO Food. Quarterly Report October 27, BIMBO Market Underperformer 2016 Price Target P$41.9

BIMBO Food. Quarterly Report October 27, BIMBO Market Underperformer 2016 Price Target P$41.9 Quarterly Report BIMBO Market Underperformer 2016 Price Target P$41.9 Price 51.51 12M Price Range 45.02 / 59.86 Shares Outstanding (Mill) 4,703.2 Market Cap (Mill) 242,262 Float 24.0% Net Debt (Mill) 72,562

More information

IOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016.

IOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016. AUSTRALIA IFL AU Price (at 06:35, 26 Oct 2016 GMT) Outperform A$8.34 Valuation A$ - DCF (WACC 8.8%, beta 1.1, ERP 5.0%, RFR 3.3%) 8.74 12-month target A$ 9.00 12-month TSR % +14.3 Volatility Index Low/Medium

More information

Food retailing. Is Rallye proof that Casino is undervalued? INDEPENDENT RESEARCH. Food retailing

Food retailing. Is Rallye proof that Casino is undervalued? INDEPENDENT RESEARCH. Food retailing INDEPENDENT RESEARCH 23rd March 2017 Food retailing Food retailing Is Rallye proof that Casino is undervalued? CASINO GUICHARD BUY FV EUR62 vs. 57 Bloomberg CO FP Reuters CASP.PA Price EUR49.79 High/Low

More information

ETFs: Regulatory (High) Impact. Commerzbank, leaders in ETF February 2018

ETFs: Regulatory (High) Impact. Commerzbank, leaders in ETF February 2018 ETFs: Regulatory (High) Impact Commerzbank, leaders in ETF February 2018 What are ETFs? Securities that track the value of an index, commodities or a basket of assets and trade like a stock on the exchange

More information

KIMBERLY CLARK DE MEXICO Re-Rating Completed; Downgrading to Hold

KIMBERLY CLARK DE MEXICO Re-Rating Completed; Downgrading to Hold Latin American Equity Research Mexico City, November 20, 2006 KIMBERLY CLARK DE MEXICO Re-Rating Completed; Downgrading to Hold Joaquín Ley* Mexico: Santander Banco Santander S.A. 5255) 5269-1921 jley@santander.com.mx

More information

Platinum Asset Management

Platinum Asset Management AUSTRALIA PTM AU Price (at 06:10, 11 Jul 2016 GMT) Neutral A$5.52 Valuation A$ - DCF (WACC 9.3%, beta 1.2, ERP 5.0%, RFR 3.3%) 5.19 12-month target A$ 5.36 12-month TSR % +2.6 Volatility Index Low/Medium

More information

Campari. The wind in its sails INDEPENDENT RESEARCH UPDATE. Food & Beverages Fair Value EUR8,4 (price EUR7.61) BUY. 4th March 2016

Campari. The wind in its sails INDEPENDENT RESEARCH UPDATE. Food & Beverages Fair Value EUR8,4 (price EUR7.61) BUY. 4th March 2016 INDEPENDENT RESEARCH UPDATE 4th March 2016 Campari The wind in its sails Food & Beverages Fair Value EUR8,4 (price EUR7.61) BUY Bloomberg CPR IM Reuters CPR.MI 12-month High / Low (EUR) 8.4 / 6.1 Market

More information

ECB Research Draghi reveals favourable TLTRO details

ECB Research Draghi reveals favourable TLTRO details Investment Research General Market Conditions 4 July 2014 ECB Research Draghi reveals favourable TLTRO details The ECB has provided additional details about the targeted LTRO (TLTRO) announced at its meeting

More information

National Industrialization Co. Diversified Operations Industrial NIC AB: Saudi Arabia 25 May 2014

National Industrialization Co. Diversified Operations Industrial NIC AB: Saudi Arabia 25 May 2014 RSI10 National Industrialization Co. NIC AB: Saudi Arabia 25 May 2014 Rating Target price Current price OVERWEIGHT SAR37.30 (18.7% upside) SAR31.40 Key themes & implications Sluggish petrochemical prices

More information

BUY Price at COB 1 October p 52-week range 39-68p. CSF Group CX6 restructuring. Technology.

BUY Price at COB 1 October p 52-week range 39-68p. CSF Group CX6 restructuring. Technology. 70 65 60 55 50 45 40 35 C SF G R O U P O N D J F M A M J J A S So u r c e : T h o m s o n R e u te r s D a ta s tr e a m Technology 2 October 2012 International Update CSF Group CX6 restructuring CSF has

More information

ContextVision. Neutral stance maintained after 3Q. 3Q14 Results analysis November 5 th 2014 Share price: NOK Target: NOK 24.

ContextVision. Neutral stance maintained after 3Q. 3Q14 Results analysis November 5 th 2014 Share price: NOK Target: NOK 24. 3Q14 Results analysis November 5 th 2014 Share price: NOK 22.00 Target: NOK 24.00 Risk: Medium ContextVision Key share data Sector Reuters Bloomberg ContextVision is a market making client of Norne Securities

More information

ECB Research ECB cutting through the lower bound Danish experiences

ECB Research ECB cutting through the lower bound Danish experiences Investment Research General Market Conditions 03 November 2015 ECB Research ECB cutting through the lower bound Danish experiences Given the turnaround in the ECB s view on deposit rate cuts, we expect

More information

EQUITY RESEARCH. Royal Dutch Shell B, Attractively Valued - Buy. Share Price: 2,202p Target Price: 2,500p (+14%) 21 September 2017

EQUITY RESEARCH. Royal Dutch Shell B, Attractively Valued - Buy. Share Price: 2,202p Target Price: 2,500p (+14%) 21 September 2017 Royal Dutch Shell B, Attractively Valued - Buy Share Price: 2,202p Target Price: 2,500p (+14%) Royal Dutch Shell B (RDSB.L) recently presented its view of global, long term energy supply and demand. Importantly,

More information

HCL Technologies. Rating: Target price: EPS: Target CMP. Rating. Rs. 826 REDUCE. Rs.760

HCL Technologies. Rating: Target price: EPS: Target CMP. Rating. Rs. 826 REDUCE. Rs.760 : price: EPS: How does our one year outlook change? HCLT registered a strong quarter with revenues growing at 6.5% qoq (4% qoq organic) including $40m contribution from Volvo, after a disappointing show

More information

Institutional Equities

Institutional Equities 4QFY18 Result Update Institutional Equities Atul Auto 30 May 2018 Reuters: ATUL.BO; Bloomberg: ATUL IN Higher Expenses Mar Profitability Atul Auto s (AAL) 4QFY18 earnings missed our expectations on account

More information

Cummins India. Source: Company Data; PL Research

Cummins India. Source: Company Data; PL Research Technology leadership, cost optimization key focus October 28, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs852

More information

EQUITY RESEARCH. Reckitt Benckiser, French s Food business sold. Share Price: 7,936p Target Price: 8,000p* (+1%) 19 July 2017

EQUITY RESEARCH. Reckitt Benckiser, French s Food business sold. Share Price: 7,936p Target Price: 8,000p* (+1%) 19 July 2017 Reckitt Benckiser, French s Food business sold Share Price: 7,936p Target Price: 8,000p* (+1%) Reckitt Benckiser (RB) has announced the sale of its French s Food business for US$ 4.2bn, which is ahead

More information

Darden Restaurants, Inc.

Darden Restaurants, Inc. Darden Restaurants, Inc. DRI: Reports Solid Performance; Expectations Were Pretty High Despite Evidence Segment Is Slowing Our View: We reiterate our OW rating following shares coming under pressure because

More information

TAV Airports EARNINGS REVIEW 4Q17. Bottom-line below consensus BUY TRY22.90

TAV Airports EARNINGS REVIEW 4Q17. Bottom-line below consensus BUY TRY22.90 EARNINGS REVIEW 4Q17 Turkey Aviation 22 February 2018 TAV Airports Bottom-line below consensus We reduce our recommendation to Hold, while keeping our target price unchanged at TRY22.90/shr. We believe

More information

Near-term pressure, but long-term outlook positive

Near-term pressure, but long-term outlook positive INDUSTRY IT CMP (as on 2 Nov 2015) Rs 1,812 Target Price Rs 2,050 Nifty 8,051 Sensex 26,559 KEY STOCK DATA Bloomberg ECLX IN No. of Shares (mn) 30 MCap (Rs bn) / ($ mn) 55/843 6m avg traded value (Rs mn)

More information

ABB LTD (INDIA) RESEARCH

ABB LTD (INDIA) RESEARCH RESULTS REVIEW Share Data Market Cap Rs. 168.6 bn Price Rs. 795.80 BSE Sensex 16,741.30 Reuters Bloomberg Avg. Volume (52 Week) ABB.BO ABB IN 0.11 mn 52-Week High/Low Rs. 856.95 / 344 Shares Outstanding

More information

O'Reilly Automotive, Inc. Quick Read: Weather Likely Weighed Upon Sales a Bit

O'Reilly Automotive, Inc. Quick Read: Weather Likely Weighed Upon Sales a Bit EQUITY RESEARCH QUARTERLY UPDATE July 27, 2016 Stock Rating: OUTPERFORM 12-18 mo. Price Target $300.00 ORLY - NASDAQ $277.51 3-5 Yr. EPS Gr. Rate 18% 52-Wk Range $284.66-$225.12 Shares Outstanding 99.4M

More information

Tupras Keep Your Optimism

Tupras Keep Your Optimism TURKEY OIL AND GAS AUGUST, 217 Tupras Common TUPRS TI Recommendation BUY Last price TRY11 Target price (from TRY19) TRY13 Upside 1% Free float 9% Market cap $,7 mln ADT, 1 days $25.2 mln Prices as of August,

More information

Colgate-Palmolive (India)

Colgate-Palmolive (India) Result Update Colgate-Palmolive (India) 27 July 218 Reuters: COLG.BO; Bloomberg: CLGT IN Tough Times Continue Colgate-Palmolive (India) or CLGT reported a mixed earnings performance in. Volume and revenue

More information

Pirelli & C Real Estate

Pirelli & C Real Estate ENN Europe Italy Real Estate 11 Nov 2004 Deutsche Bank Pirelli & C Real Estate Real Estate, Reloaded Recommendation Hold Price at 10 Nov 2004 EUR 35.00 Target Price EUR 39.20 Ticker/Code PCRE.MI Year End

More information

2Q16 Highlights: 12M FWD EV/EBITDA 12M PRICE PERFORMANCE VS. IPC P/E

2Q16 Highlights: 12M FWD EV/EBITDA 12M PRICE PERFORMANCE VS. IPC P/E GISSA Market Outperformer 12M FWD Price Target P$45.0 Price 31.4 12M Price Range 29.5/ 33.09 Shares Outstanding 356 Market Cap (Mill) 11,169 Float 19.5% Net Debt (Mill) 46 EV (Mill) 11,164 Dividend Yield

More information

DKK: Unchanged appetite for Danish bonds among foreign investors in September

DKK: Unchanged appetite for Danish bonds among foreign investors in September DKK: Unchanged appetite for Danish bonds among foreign investors in September Jens Nærvig Pedersen Analyst Danske Bank Markets jenpe@danskebank.dk +45 45 12 8 61 28 October 213 Important disclosures and

More information

Our thesis considers the following:

Our thesis considers the following: Quarterly Report OMA Market Underperformer 2016 Price Target P$108.8 Price 114.23 12M Price Range 77.19 / 115.63 Shares Outstanding (Mill) 392.2 Market Cap (Mill) 44,796 Float 46% Net Debt (Mill) 2,782

More information

FLASH NOTE EQUITY RESEARCH. OUTPERFORM Price target 6.40 Price Elanix Biotechnologies AG (ELN-DE) Updates from webcast include financial outlook

FLASH NOTE EQUITY RESEARCH. OUTPERFORM Price target 6.40 Price Elanix Biotechnologies AG (ELN-DE) Updates from webcast include financial outlook ELANIX BIOTECHNOLOGIES AG Biotechnology 8 August 2018 09:54 BST FLASH NOTE Elanix Biotechnologies AG (ELN-DE) Updates from webcast include financial outlook OUTPERFORM Price target 6.40 Price 2.72 KEY

More information

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015 RESULTS REVIEW 4QFY15 29 APR 2015 Marico Kaya INDUSTRY FMCG CMP (as on 28 Apr 2015) Rs 1,635 Target Price Rs 1,823 Nifty 8,240 Sensex 27,226 KEY STOCK DATA Bloomberg MAKA IN No. of Shares (mn) 13 MCap

More information

CITY OF LONDON INVESTMENT GROUP

CITY OF LONDON INVESTMENT GROUP 9 October 2018 Financial Services Daily CLIG.L Line, CLIG.L, Trade Price(Last), 09/10/2018, 409.00, N/A, N/A Market data Source: Eikon Thomson Reuters EPIC/TKR CLIG Price (p) 400.0 12m High (p) 454.0 12m

More information

Cummins India. Growth/margin bottoming. Source: Company Data; PL Research

Cummins India. Growth/margin bottoming. Source: Company Data; PL Research Growth/margin bottoming May 25, 2018 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Shreyans Jain shreyansjain@plindia.com +91 22 66322256 Rating BUY Price Rs704 Target Price Rs928 Implied Upside 31.8%

More information

The Company for Cooperative Insurance Insurance TAWUNIYA AB 8010.SE

The Company for Cooperative Insurance Insurance TAWUNIYA AB 8010.SE Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 Recommendation Overweight Current Price (SAR) 82.60 Target Price (SAR) 101.13 Upside/Downside (%) 22.4% As of

More information

Convertible bonds gaining from growth as rates rise

Convertible bonds gaining from growth as rates rise Insight Convertible bonds gaining from growth as rates rise June 2015 In a rising rate environment, convertible bonds may offer investors a measure of duration protection and the potential for attractive

More information

Markets catch-up to the Fed. Market Insight

Markets catch-up to the Fed. Market Insight Markets catch-up to the Fed The shift higher and steepening in the US Treasury yield curve since the turn of the year primarily reflects the market catching up with the Federal Reserve s (Fed) guidance

More information

Results Review. 3QFY13: Downsizing its workforce. Technology Bloomberg Ticker: UNI MK Bursa Code: November 2013

Results Review. 3QFY13: Downsizing its workforce. Technology Bloomberg Ticker: UNI MK Bursa Code: November 2013 Results Review (Member of Alliance Bank group) PP7766/03/2013 (032116) 8 November 2013 Analyst Toh Woo Kim wookim@alliancefg.com +603 2604 3917 12-month upside potential Previous target price 0.89 Revised

More information

Indraprastha Gas. Growth traction continues. Source: Company Data; PL Research

Indraprastha Gas. Growth traction continues. Source: Company Data; PL Research Growth traction continues June 28, 216 Avishek Datta avishekdatta@plindia.com +91 22 66322254 Rating BUY Price Rs65 Target Price Rs632 Implied Upside 4.5% Sensex 26,43 Nifty 8,95 (Prices as on June 27,

More information

Fee income offsets margin pressure

Fee income offsets margin pressure Apr 15 Jun 15 Aug 15 Oct 15 Dec 15 Feb 16 DUBAI ISLAMIC BANK Fee income offsets margin pressure Results update 1Q2016 Banks UAE Dubai Islamic Bank (DIB) reported profit at AED875mn was in-line with our

More information

Market Pulse. Inter. FFBL: Weak pricing power; Sell. Pakistan Fertilizer

Market Pulse. Inter. FFBL: Weak pricing power; Sell.   Pakistan Fertilizer Inter Pakistan Fertilizer FFBL: Weak pricing power; Sell Research Entity Number REP-85 We resume coverage on Fauji Fertilizer Bin Qasim Ltd (FFBL), the only local producer of DAP fertilizer, with a Sell

More information

Persistent Systems. Growth led by Enterprise Retain BUY. Source: Company Data; PL Research

Persistent Systems. Growth led by Enterprise Retain BUY. Source: Company Data; PL Research Growth led by Enterprise Retain BUY October 26, 20 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Hussain Kagzi hussainkagzi@plindia.com +91 22 66322242 Rating BUY Price Rs669 Target Price Rs780

More information

Air France-KLM. Hold TP 6.50 CP 7.59 (Close 21 October 2013) Q3 due 31 October More restructuring needed. Equity Research Quick Bite Preview

Air France-KLM. Hold TP 6.50 CP 7.59 (Close 21 October 2013) Q3 due 31 October More restructuring needed. Equity Research Quick Bite Preview Equity Research Quick Bite Preview 22 October 2013 Air France-KLM Q3 due 31 October More restructuring needed Supported by lower fuel costs and the ramp up in cost savings, we expect Q3 to deliver a solid

More information

EQCR Iberia News. Reduce (Reduce)

EQCR Iberia News. Reduce (Reduce) EQCR Iberia News SM 8.50 Equity Research Espresso IDR comment F Full report Indra Reduce (Reduce) Spain IT software & services MCAP EUR 1.7bn Target Price EUR 8.50 06 November 2015 Current Price Up/downside

More information

3,951 EBITDA 1,174 1,153 1,260 1,284 1,332 Outst shares (mn) 57 EBIT Free float (%)

3,951 EBITDA 1,174 1,153 1,260 1,284 1,332 Outst shares (mn) 57 EBIT Free float (%) European Equity Research ACCIONA Facing a Good 2017E Spain Electricity November 7, 2016 (07:15 CET) BUY CURRENT PRICE: 69.01 TARGET PRICE: 82.40 ANA released 9M16 results on Nov 4 and we have adjusted

More information

Economic activity gathers pace

Economic activity gathers pace Produced by the Economic Research Unit October 2014 A quarterly analysis of trends in the Irish economy Economic activity gathers pace Positive data flow Recovery broadening out GDP growth revised up to

More information

ITC. Rating: Target price: EPS: Relative better visibility despite the smoke, Maintain BUY CMP. Target. Rating. Rs.389. Buy. Rs.

ITC. Rating: Target price: EPS: Relative better visibility despite the smoke, Maintain BUY CMP. Target. Rating. Rs.389. Buy. Rs. : price: EPS: Relative better visibility despite the smoke, Maintain BUY ITC reported revenues of Rs.~87.2bn (+13% y-o-y), operating profits of Rs.32.8bn (+15% y-o-y) and PAT of Rs.~23.8bn (+16% y-o-y).

More information

Polish Banks. Upgrading ratings for CHF exposed banks. Sector update. Banks Poland

Polish Banks. Upgrading ratings for CHF exposed banks. Sector update. Banks Poland Banks Poland Polish Banks Sector update We change our assumption of CHF related sector loss to PLN 2bn from PLN 4bn previously. We upgrade all of the CHF exposed banks: PKO BP to Accumulate from Neutral,

More information

E-FIT trial results indicate no clinical improvement

E-FIT trial results indicate no clinical improvement NEXSTIM OYJ Medical Technology 3 September 2018 11:44 BST FLASH NOTE Nexstim OYJ (NXTMH-FI) E-FIT trial results indicate no clinical improvement OUTPERFORM Price target 1.23 Price 0.23 KEY TAKEAWAY Today,

More information

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance 2QFY19 Result Update Gillette India 13 February 2019 Reuters: GILE.NS; Bloomberg: GILL IN Marketing Investments Mask Improved Top-line Performance Gillette India s (GILL) 2QFY19 operating and net earnings

More information

2015: A rosy outlook. Vlad Muscalu Chief Economist

2015: A rosy outlook. Vlad Muscalu Chief Economist 215: A rosy outlook Vlad Muscalu Chief Economist GDP forecasting a funny rollercoaster Talking about GDP Y = C + I + G + X - M GDP = Private Consumption + Investment + +Government Consumption + Exports

More information

Siemens. Railways and T&D driving inflows. Source: Company Data; PL Research

Siemens. Railways and T&D driving inflows. Source: Company Data; PL Research Railways and T&D driving inflows November 23, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs1,055 Target Price Rs1,230

More information

Asian Paints. Source: Company Data; PL Research

Asian Paints. Source: Company Data; PL Research Premium Valuations to sustain, Accumulate May, 17 Amnish Aggarwal amnishaggarwal@plindia.com +91 Gaurav Jogani gauravjogani@plindia.com +91 8 Rating Accumulate Price Rs1,18 Target Price Rs1,171 Implied

More information

Ahluwalia Contracts (India)

Ahluwalia Contracts (India) May-14 Jul-14 Aug-14 Sep-14 Oct-14 Dec-14 Jan-15 Feb-15 Apr-15 May-15 India Research Infrastructure May 22, 215 QUARTERLY REVIEW Bloomberg: AHLU IN Reuters: AHLU.BO BUY Better performance ahead ACIL posted

More information

Almarai Steady performance

Almarai Steady performance RSI10 ALMARAI AB: Saudi Arabia Rating Target price Current price NEUTRAL SAR55.05 (-4.59% upside) SAR57.66 Key themes & implications Almarai reported a positive top-line in Q1 2016, showing resilience

More information

Saudi Company for Hardware (SACO) CMP: SAR 72, Target Price: SAR 62

Saudi Company for Hardware (SACO) CMP: SAR 72, Target Price: SAR 62 Saudi Company for Hardware (SACO) CMP: SAR 72, Target Price: SAR 62 Raneem Seroor +973-17515000 (extn - 5096) rseroor@sicobank.com GCC Equities Consumer Goods Company Update 20 December 2018 Time to book

More information

Commerzbank Energy & Carbon Seminar

Commerzbank Energy & Carbon Seminar Commerzbank Energy & Carbon Seminar Trends, challenges and outlook for the energy and carbon markets in 2016 marketing material for information purposes only Ingo Ramming A 5 bet on Leicester City winning

More information

MULTI-ASSET DIVERSIFIED GLOBAL CERTIFICATE 11

MULTI-ASSET DIVERSIFIED GLOBAL CERTIFICATE 11 JANUARY 2018 MULTI-ASSET DIVERSIFIED GLOBAL CERTIFICATE 11 Gain exposure to a broadly diversified investment universe through the BNP Paribas Multi-Asset Diversified vol 8 USD FX Hedged Future Index Issued

More information

Wijaya Karya (WIKA IJ)

Wijaya Karya (WIKA IJ) Equity Indonesia Construction Wijaya Karya (WIKA IJ) BUY (Unchanged) Stock Data Target price (Rp) Prior TP (Rp) Shareprice (Rp) Rp2,900 Rp2,900 Rp1,745 Upside/downside (%) +66.2 Sharesoutstanding (m) 8,970

More information

Standalone Quarterly results (YE Mar) 1QFY14 1QFY15 % yoy FY13 FY14 % yoy

Standalone Quarterly results (YE Mar) 1QFY14 1QFY15 % yoy FY13 FY14 % yoy India I Equities Healthcare Result Update 15 July 2014 Unichem Laboratories Recovery in sight; Buy Key takeaways Results slightly above our estimates. Unichem Laboratories (Unichem) revenue grew 9.6% yoy,

More information

Key estimate revision. Year CY14 87,383 11,148 6, CY15E 1,20,126 17,838 9,

Key estimate revision. Year CY14 87,383 11,148 6, CY15E 1,20,126 17,838 9, : price: EPS: How does our one year outlook change? We retain our positive view on EIM on the back of expected improvement in volume and margin at Royal Enfield (RE) and expected revival in VECV on the

More information

Mphasis. Source: Company Data; PL Research

Mphasis. Source: Company Data; PL Research Setting path for growth in Direct Channel, Retain Accumulate June 18, 2015 Shashi Bhusan shashibhusan@plindia.com +91 22 66322300 Hussain Kagzi hussainkagzi@plindia.com +91 22 66322242 Rating Accumulate

More information

CITY OF LONDON INVESTMENT GROUP

CITY OF LONDON INVESTMENT GROUP 21 January 2019 Financial Services Daily CLIG.L Line, CLIG.L, Trade Price(Last), 21/01/2019, 384.20, +11.00, (+2.90%) 23/01/2017-21/01/2019 (LON) Price GBp CITY OF LONDON INVESTMENT GROUP F M A M J J A

More information

Mahindra & Mahindra. Source: Company Data; PL Research

Mahindra & Mahindra. Source: Company Data; PL Research Tractors drive Q2 performance; Accumulate November 11, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating Accumulate Price Rs1,242 Target Price Rs1,503 Implied Upside 21.0% Sensex 26,819 Nifty

More information

Flash Economics. What must we assume if we do not believe long-term interest rates will rise sharply in the peripheral eurozone

Flash Economics. What must we assume if we do not believe long-term interest rates will rise sharply in the peripheral eurozone December - 7 What must we assume if we do not believe long-term interest rates will rise sharply in the peripheral eurozone countries? If we believe a sharp rise in long-term interest rates in the peripheral

More information

FX Viewpoint. Wednesday, October 12, Asia Net portfolio capital inflow update

FX Viewpoint. Wednesday, October 12, Asia Net portfolio capital inflow update FX Viewpoint Wednesday, October 12, 216 Asia Net portfolio capital inflow update Corporate FX & Structured Products Tel: 69-1888 / 1881 Fixed Income & Structured Products Tel: 69-181 The net capital inflow

More information